Publications

May 2023
Case

Legacy Partners

By: Royce Yudkoff and Richard S. Ruback

Stephen Holbrook and Austin Pulsipher (both HBS '19) had been leading Nutrishare since acquiring the company six months earlier in mid-2021. The company, based in Sacramento CA, was a compounding pharmacy serving Total Parenteral Nutrition ("TPN") patients nationwide.... View Details

Keywords: Acquisition; Growth and Development Strategy; Competitive Strategy; Business or Company Management; Pharmaceutical Industry

May 4, 2023
Article

Falling Insulin Prices—What Just Happened?

By: Leemore S. Dafny

Recently, more than 100 years after insulin was developed, manufacturers announced price reductions for insulin products. Pressure to reduce prices had long been building, so why would they act now? View Details

Keywords: Price; Health Care and Treatment; Public Opinion; Demand and Consumers; Pharmaceutical Industry

Find at Harvard

Register to Read

January 2023
Case

Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery

By: Regina Herzlinger and Brian Walker

What should a successful executive (HBS Baker Scholar) assess as her next move as the CEO of a firm with a promising and yet uncertain new drug? Amy Burroughs’ mandate to successfully commercialize Cleave Therapeutics’ drug for a cancer with no current successful... View Details

Keywords: Product Development; Leadership; Health Testing and Trials; Research and Development; Risk and Uncertainty; Financial Condition; Partners and Partnerships; Pharmaceutical Industry

September 2020
Case

Merck: COVID-19 Vaccines

By: Willy C. Shih

COVID-19 infections were still climbing across the U.S. and many other parts of the world in September 2020, and it seemed that every time Ken Frazier, the CEO of Merck & Co. consented to an interview in recent months he always seemed to hear the same question,... View Details

Keywords: Vaccines; COVID-19 Pandemic; Health Pandemics; Health Testing and Trials; Innovation and Management; Innovation Strategy; Technological Innovation; Business Strategy; Product Launch; Pharmaceutical Industry

March 2018 (Revised January 2019)
Case

Gilead Mexico

By: Michael Chu and V. Kasturi Rangan

With a breakthrough cure for Hepatitis C listing in the U.S. at $1,000/pill, Gilead must now solve the issue of making it available to patients across the world, much as it did for its blockbuster HIV/AIDS antiretrovirals. For Erik Musalem, the new general manager of... View Details

Keywords: Health Care and Treatment; Price; Strategy; Management; Pharmaceutical Industry; Mexico

January 2017
Supplement

Terrapin Laboratory: Exercise

By: Joseph B. Fuller and Christopher Payton

In this exercise, we examine the capital requirements of Terrapin Laboratory as they contemplate entering into a new market segment. The company is faced with two potential financing options which have different effects on the ownership structure of the company.... View Details

Keywords: Business Growth; Entrepreneurial Management; Growth Strategy; Market Entry; Venture Capital; Market Entry and Exit; Entrepreneurship; Health Testing and Trials; Growth and Development Strategy; Pharmaceutical Industry

February 2011 (Revised October 2012)
Exercise

Treu Pharma: Role for Stef Kuehne

By: Andrew Wasynczuk and Shaun Patrick Hughes

Keywords: Pharmaceutical Industry

October 2010 (Revised November 2010)
Background Note

Plavix: Drugs in the Age of Personalized Medicine

By: Richard G. Hamermesh, Mara G. Aspinall and Rachel Gordon

PIavix, one of the world's best selling drugs in 2010, appears to have a limited future. Its patent was due to expire soon, and recently new data had been discovered that indicated that a small subset of the population would be at risk for stroke, heart attack, or even... View Details

Keywords: Health Care and Treatment; Product Positioning; Business and Government Relations; Genetics; Competitive Strategy; Pharmaceutical Industry

September 2010
Teaching Note

Alnylam Pharmaceuticals: Building Value from the IP Estate (TN)

By: Willy C. Shih

Teaching Note for 611009. View Details

Keywords: Value; Patents; Corporate Strategy; Competition; Research and Development; Lawsuits and Litigation; Pharmaceutical Industry; United States

December 2009 (Revised April 2010)
Teaching Note

GlaxoSmithKline: Reorganizing Drug Discovery (TN) (A) and (B)

By: Robert S. Huckman

Teaching Note for [605074] and [605075]. View Details

Keywords: Restructuring; Health; Pharmaceutical Industry

February 2009
Teaching Note

Syndexa and Technology Transfer at Harvard University (TN)

By: Richard G. Hamermesh

Teaching Note for [808073]. View Details

Keywords: Agreements and Arrangements; Commercialization; Science-Based Business; Research; Rights; Pharmaceutical Industry

2000
Chapter

Measuring Competence? Exploring Firm Effects in Drug Discovery

By: Rebecca M. Henderson and Iain Cockburn

Keywords: Competency and Skills; Measurement and Metrics; Research and Development; Innovation and Invention; Pharmaceutical Industry

Find at Harvard

Read Now

December 2008 (Revised October 2013)
Case

Amylin Pharmaceuticals: Diabetes and Beyond (A)

By: Richard G. Hamermesh and Rachel Gordon

Ginger Graham, CEO of Amylin Pharmaceuticals, joined the company with the expectation of taking the company's signature drug, Symlin, to market. However, unforeseen regulatory challenges have put the approval process in jeopardy. At the same time, the company has a... View Details

Keywords: Regulations; Drug Regulations; Symlin; Negotiation; Governing Rules, Regulations, and Reforms; Resource Allocation; Negotiation Deal; Product Development; Research and Development; Commercialization; Pharmaceutical Industry; United States

September 2008
Case

Pfizer Inc: Building an Innovation Center

By: Stefan H. Thomke and Ashok Nimgade

The case describes Pfizer's efforts to build and run an innovation center in Cambridge, Massachusetts. As the center goes through different periods of leadership and strategic models, its relationship with the corporation and other research sites is explored. The case... View Details

Keywords: Innovation and Management; Innovation Strategy; Leadership; Organizational Culture; Research and Development; Pharmaceutical Industry; Cambridge